INVOKANA (Janssen Pharmaceuticals, Inc.)
Welcome to the PulseAid listing for the INVOKANA drug offered from Janssen Pharmaceuticals, Inc.. This Sodium-Glucose Cotransporter 2 Inhibitor [EPC],Sodium-Glucose Transporter 2 Inhibitors [MoA],P-Glycoprotein Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Janssen Pharmaceuticals, Inc. |
| NON-PROPRIETARY NAME: | canagliflozin |
| SUBSTANCE NAME: | CANAGLIFLOZIN |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Sodium-Glucose Cotransporter 2 Inhibitor [EPC],Sodium-Glucose Transporter 2 Inhibitors [MoA],P-Glycoprotein Inhibitors [MoA] |
| ROUTE: | ORAL |
| DOSAGE FORM: | TABLET, FILM COATED |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2013-03-29 |
| END MARKETING DATE: | 0000-00-00 |
INVOKANA HUMAN PRESCRIPTION DRUG Details:
| Item Description | INVOKANA from Janssen Pharmaceuticals, Inc. |
| LABELER NAME: | Janssen Pharmaceuticals, Inc. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 100(mg/1) |
| START MARKETING DATE: | 2013-03-29 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 50458-140_a68673e8-e33b-4978-8593-01318d94a53f |
| PRODUCT NDC: | 50458-140 |
| APPLICATION NUMBER: | NDA204042 |
Other CANAGLIFLOZIN Pharmaceutical Manufacturers / Labelers:
